{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:23:44Z","timestamp":1785507824934,"version":"3.56.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s41669-026-00651-0","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T13:49:09Z","timestamp":1776174549000},"page":"733-748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3813-7921","authenticated-orcid":false,"given":"Jeanine","family":"Flanigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9341-4836","authenticated-orcid":false,"given":"Sarah","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0189-9065","authenticated-orcid":false,"given":"Fatemeh","family":"Mirzayeh Fashami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5451-4670","authenticated-orcid":false,"given":"Anna","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3847-6766","authenticated-orcid":false,"given":"Lamees","family":"Almuallem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4487-6595","authenticated-orcid":false,"given":"Mike","family":"Tindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0782-8816","authenticated-orcid":false,"given":"Marion","family":"Schauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8661-0560","authenticated-orcid":false,"given":"Edward","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0823-8086","authenticated-orcid":false,"given":"Gary H.","family":"Lyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"7","key":"651_CR1","doi-asserted-by":"publisher","first-page":"816","DOI":"10.2174\/18735592MTEwrOTUbx","volume":"22","author":"S Huidrom","year":"2021","unstructured":"Huidrom S, Beg MA, Masood T. Post-menopausal osteoporosis and probiotics. Curr Drug Targets. 2021;22(7):816\u201322.","journal-title":"Curr Drug Targets"},{"issue":"11","key":"651_CR2","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1002\/jbmr.2269","volume":"29","author":"NC Wright","year":"2014","unstructured":"Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520\u20136.","journal-title":"J Bone Miner Res"},{"issue":"9","key":"651_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10192","volume":"3","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki EM, Ortendahl JD, Vanderpuye-Orgle J, Grauer A, Arellano J, Lemay J, et al. Healthcare policy changes in osteoporosis can improve outcomes and reduce costs in the United States. JBMR Plus. 2019;3(9):e10192.","journal-title":"JBMR Plus."},{"key":"651_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, et al. American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update. Endocr Pract. 2020;26:1\u201346.","journal-title":"Endocr Pract"},{"key":"651_CR5","unstructured":"Food and Drug Administration. FDA label: Fosamax. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/020560s070lbl.pdf. Accessed 5 Jan 2024."},{"key":"651_CR6","unstructured":"Food and Drug Administration. FDA label: Actonel. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/020835s052lbl.pdf. Accessed 1 May 2024."},{"key":"651_CR7","unstructured":"Food and Drug Administration. FDA label: Boniva. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021455s021lbl.pdf. Accessed 1 May 2024."},{"key":"651_CR8","unstructured":"Food and Drug Administration. FDA label: Reclast. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021817s028lbl.pdf. Accessed 1 May 2024."},{"key":"651_CR9","unstructured":"Food and Drug Administration. FDA approved label: Prolia. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125320s216lbl.pdf. Accessed 9 May 2024."},{"issue":"4","key":"651_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027049","volume":"9","author":"F Fatoye","year":"2019","unstructured":"Fatoye F, Smith P, Gebrye T, Yeowell G. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open. 2019;9(4):e027049.","journal-title":"BMJ Open"},{"key":"651_CR11","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s40520-019-01205-7","volume":"31","author":"S Gonnelli","year":"2019","unstructured":"Gonnelli S, Caffarelli C, Letizia Mauro G, Di Munno O, Malavolta N, Migliaccio S, et al. Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study. Aging Clin Exp Res. 2019;31:1541\u20137.","journal-title":"Aging Clin Exp Res"},{"key":"651_CR12","unstructured":"IBM Micromedex Red Book. Red Book: IBM Watson Health\u2122, an IBM Company; 2024."},{"issue":"4","key":"651_CR13","doi-asserted-by":"publisher","first-page":"334","DOI":"10.4065\/77.4.334","volume":"77","author":"C Simonelli","year":"2002","unstructured":"Simonelli C, Killeen K, Mehle S, Swanson L. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc. 2002;77(4):334\u20138.","journal-title":"Mayo Clin Proc"},{"issue":"20","key":"651_CR14","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1001\/archinte.165.20.2414","volume":"165","author":"DH Solomon","year":"2005","unstructured":"Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165(20):2414\u20139.","journal-title":"Arch Intern Med"},{"issue":"4","key":"651_CR15","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1053\/j.gastro.2005.06.013","volume":"129","author":"KE Hall","year":"2005","unstructured":"Hall KE, Proctor DD, Fisher L, Rose S. American Gastroenterological Association future trends committee report: effects of aging of the population on gastroenterology practice, education, and research. Gastroenterology. 2005;129(4):1305\u201338.","journal-title":"Gastroenterology"},{"key":"651_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2318-13-36","volume":"13","author":"JA Knopp-Sihota","year":"2013","unstructured":"Knopp-Sihota JA, Cummings GG, Homik J, Voaklander D. The association between serious upper gastrointestinal bleeding and incident bisphosphonate use: a population-based nested cohort study. BMC Geriatr. 2013;13:1\u201312.","journal-title":"BMC Geriatr"},{"issue":"1","key":"651_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1185\/03007995.2013.851074","volume":"30","author":"ES Siris","year":"2014","unstructured":"Siris ES, Modi A, Tang J, Gandhi S, Sen S. Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis. Curr Med Res Opin. 2014;30(1):123\u201330.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"651_CR18","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1210\/jc.2010-0597","volume":"95","author":"I Reid","year":"2010","unstructured":"Reid I, Gamble G, Mesenbrink P, Lakatos P, Black D. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab. 2010;95(9):4380\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"651_CR19","doi-asserted-by":"crossref","unstructured":"Levitt L, Altman D. Complexity in the US health care system is the enemy of access and affordability. JAMA Health Forum; 2023. p. e234430.","DOI":"10.1001\/jamahealthforum.2023.4430"},{"issue":"6","key":"651_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40273-015-0380-x","volume":"34","author":"J Mestre-Ferrandiz","year":"2016","unstructured":"Mestre-Ferrandiz J, Towse A, Berdud M. Biosimilars: how can payers get long-term savings? Pharmacoeconomics. 2016;34(6):609\u201316.","journal-title":"Pharmacoeconomics"},{"key":"651_CR21","unstructured":"Food and Drug Administration. FDA label: Jubbonti. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761362s000lbl.pdf. Accessed 1 May 2024."},{"key":"651_CR22","doi-asserted-by":"crossref","unstructured":"Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3.","DOI":"10.7249\/PE264"},{"key":"651_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/627631","author":"S Silverman","year":"2015","unstructured":"Silverman S, Agodoa I, Kruse M, Parthan A, Orwoll E. Denosumab for elderly men with osteoporosis: a cost-effectiveness analysis from the US payer perspective. J Osteoporos. 2015. https:\/\/doi.org\/10.1155\/2015\/627631.","journal-title":"J Osteoporos"},{"key":"651_CR24","unstructured":"National Institute for Health and Care Excellence. Denosumab for the prevention of osteoporotic fractures in postmenopausal women2010."},{"key":"651_CR25","unstructured":"Food and Drug Administration. Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities Questions and Answers: Guidance for Industry and Review Staff; 2018."},{"issue":"1","key":"651_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/23814683211061097","volume":"7","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. MDM Policy Pract. 2022;7(1):23814683211061097.","journal-title":"MDM Policy Pract"},{"issue":"15","key":"651_CR27","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","volume":"276","author":"MC Weinstein","year":"1996","unstructured":"Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276(15):1253\u20138.","journal-title":"JAMA"},{"issue":"10","key":"651_CR28","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103.","journal-title":"JAMA"},{"issue":"8","key":"651_CR29","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756\u201365.","journal-title":"N Engl J Med"},{"key":"651_CR30","unstructured":"Canada's Drug Agency. Common Drug Review: Denosumab (Prolia); 2015."},{"issue":"29","key":"651_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta24290","volume":"24","author":"S Davis","year":"2020","unstructured":"Davis S, Simpson E, Hamilton J, Martyn-St James M, Rawdin A, Wong R, et al. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. Health Technol Assess. 2020;24(29):1.","journal-title":"Health Technol Assess"},{"issue":"1","key":"651_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00198-018-4744-x","volume":"30","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Reginster J-Y, Tosteson A, Bukata S, Saag K, Gold D, et al. Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts\u2019 consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporos Int. 2019;30(1):45\u201357.","journal-title":"Osteoporos Int"},{"issue":"5","key":"651_CR33","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","volume":"104","author":"P Barrionuevo","year":"2019","unstructured":"Barrionuevo P, Kapoor E, Asi N, Alahdab F, Mohammed K, Benkhadra K, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab. 2019;104(5):1623\u201330.","journal-title":"J Clin Endocrinol Metab"},{"key":"651_CR34","first-page":"781","volume-title":"Network meta-analysis of pharmacological agents for osteoporosis treatment and fracture prevention","author":"X-c Yang","year":"2016","unstructured":"Yang X-c, Deng Z-h, Wen T, Luo W, Xiao W-f, Zhao R-b, et al. Network meta-analysis of pharmacological agents for osteoporosis treatment and fracture prevention. Basel: S. Karger AG; 2016. p. 781\u201395."},{"issue":"2","key":"651_CR35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40618-022-01910-7","volume":"46","author":"C Luo","year":"2023","unstructured":"Luo C, Qin S-X, Wang Q-Y, Li Y-F, Qu X-L, Yue C, et al. Cost-effectiveness analysis of five drugs for treating postmenopausal women in the United States with osteoporosis and a very high fracture risk. J Endocrinol Investig. 2023;46(2):367\u201379.","journal-title":"J Endocrinol Investig"},{"key":"651_CR36","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40258-013-0047-8","volume":"11","author":"A Parthan","year":"2013","unstructured":"Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Appl Health Econ Health Policy. 2013;11:485\u201397.","journal-title":"Appl Health Econ Health Policy"},{"issue":"5","key":"651_CR37","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s00223-023-01140-w","volume":"113","author":"R Hikmet","year":"2023","unstructured":"Hikmet R, Harsl\u00f8f T, Langdahl BL. The effect of effervescent and buffered alendronate compared to conventional alendronate on markers of bone turnover: a randomized non-inferiority trial. Calcif Tissue Int. 2023;113(5):532\u20139.","journal-title":"Calcif Tissue Int"},{"key":"651_CR38","unstructured":"Centers for Medicare & Medicaid Services. https:\/\/www.cms.gov\/. Accessed 1 May 2024."},{"key":"651_CR39","unstructured":"Amgen. 2022 Biosimilar trend report 2022."},{"key":"651_CR40","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00198-012-2067-x","volume":"24","author":"S Brenneman","year":"2013","unstructured":"Brenneman S, Yurgin N, Fan Y. Cost and management of males with closed fractures. Osteoporos Int. 2013;24:825\u201333.","journal-title":"Osteoporos Int"},{"issue":"12","key":"651_CR41","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1359\/jbmr.090523","volume":"24","author":"ML Kilgore","year":"2009","unstructured":"Kilgore ML, Morrisey MA, Becker DJ, Gary LC, Curtis JR, Saag KG, et al. Health care expenditures associated with skeletal fractures among Medicare beneficiaries, 1999\u20132005. J Bone Miner Res. 2009;24(12):2050\u20135.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"651_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/13696998.2019.1651122","volume":"23","author":"A Stopeck","year":"2020","unstructured":"Stopeck A, Brufsky A, Kennedy L, Bhatta S, Bhowmik D, Buchanan J, et al. Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ. 2020;23(1):37\u201347.","journal-title":"J Med Econ"},{"issue":"4","key":"651_CR43","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/0272989X06290497","volume":"26","author":"J Hanmer","year":"2006","unstructured":"Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Mak. 2006;26(4):391\u2013400.","journal-title":"Med Decis Mak"},{"key":"651_CR44","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s00223-008-9117-6","volume":"82","author":"M Hiligsmann","year":"2008","unstructured":"Hiligsmann M, Ethgen O, Richy F, Reginster J-Y. Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int. 2008;82:288\u201392.","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"651_CR45","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1262-3636(07)70154-4","volume":"30","author":"W Redekop","year":"2004","unstructured":"Redekop W, Stolk E, Kok E, Lovas K, Kalo Z, Busschbach J. Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes Metab. 2004;30(6):549\u201356.","journal-title":"Diabetes Metab"},{"issue":"2","key":"651_CR46","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/j.1572-0241.2001.03516.x","volume":"96","author":"PW Groeneveld","year":"2001","unstructured":"Groeneveld PW, Lieu TA, Fendrick MA, Hurley LB, Ackerson LM, Levin TR, et al. Quality of life measurement clarifies the cost-effectiveness of helicobacter pylorieradication in peptic ulcer disease and uninvestigated dyspepsia. Am J Gastroenterol. 2001;96(2):338\u201347.","journal-title":"Am J Gastroenterol"},{"key":"651_CR47","doi-asserted-by":"crossref","unstructured":"Davis S, James M-S, Sanderson J, Stevens J, Goka E, Rawdin A, et al. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. 2016.","DOI":"10.3310\/hta20780"},{"key":"651_CR48","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00198-009-1032-9","volume":"21","author":"B Ettinger","year":"2010","unstructured":"Ettinger B, Black D, Dawson-Hughes B, Pressman A, Melton L. Updated fracture incidence rates for the US version of FRAX\u00ae. Osteoporos Int. 2010;21:25\u201333.","journal-title":"Osteoporos Int"},{"issue":"3","key":"651_CR49","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge R, Dawson\u2010Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis\u2010related fractures in the United States, 2005\u20132025. J Bone Miner Res. 2007;22(3):465\u201375.","journal-title":"J Bone Miner Res"},{"key":"651_CR50","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00198-016-3772-7","volume":"28","author":"T Mori","year":"2017","unstructured":"Mori T, Crandall C, Ganz D. Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA. Osteoporos Int. 2017;28:585\u201395.","journal-title":"Osteoporos Int"},{"key":"651_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115286","volume":"134","author":"E S\u00f6reskog","year":"2020","unstructured":"S\u00f6reskog E, Str\u00f6m O, Sp\u00e5ng\u00e9us A, \u00c5kesson KE, Borgstr\u00f6m F, Banefelt J, et al. Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older. Bone. 2020;134:115286.","journal-title":"Bone"},{"key":"651_CR52","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11657-017-0316-5","volume":"12","author":"E Durden","year":"2017","unstructured":"Durden E, Pinto L, Lopez-Gonzalez L, Juneau P, Barron R. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Arch Osteoporos. 2017;12:22.","journal-title":"Arch Osteoporos"},{"key":"651_CR53","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00198-020-05780-8","volume":"32","author":"E S\u00f6reskog","year":"2021","unstructured":"S\u00f6reskog E, Lindberg I, Kanis J, \u00c5kesson K, Willems D, Lorentzon M, et al. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden. Osteoporos Int. 2021;32:585\u201394.","journal-title":"Osteoporos Int"},{"issue":"1","key":"651_CR54","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00198-021-06102-2","volume":"33","author":"E Boschitsch","year":"2022","unstructured":"Boschitsch E, Naegele O, Klinger A, Brix-Samoylenko H. Long-term persistence with denosumab: real-world data from the Austrian Osteoporosis Clinic (AOC). A retrospective data analysis. Osteoporos Int. 2022;33(1):263\u201372.","journal-title":"Osteoporos Int"},{"issue":"8","key":"651_CR55","first-page":"596","volume":"17","author":"KE Martin","year":"2011","unstructured":"Martin KE, Yu J, Campbell E, Abarca J, White J. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost. J Manag Care Pharm. 2011;17(8):596\u2013609.","journal-title":"J Manag Care Pharm"},{"key":"651_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11657-020-00733-4","volume":"15","author":"A Sp\u00e5ngeus","year":"2020","unstructured":"Sp\u00e5ngeus A, Johansson S, Woisetschl\u00e4ger M. Adherence to and persistence with zoledronic acid treatment for osteoporosis\u2014reasons for early discontinuation. Arch Osteoporos. 2020;15:1\u20136.","journal-title":"Arch Osteoporos"},{"issue":"8","key":"651_CR57","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/j.1742-1241.2006.01059.x","volume":"60","author":"A Cooper","year":"2006","unstructured":"Cooper A, Drake J, Brankin E, Investigators p. Treatment persistence with once\u2010monthly ibandronate and patient support vs. once\u2010weekly alendronate: results from the PERSIST study. Int J Clin Pract. 2006;60(8):896\u2013905.","journal-title":"Int J Clin Pract"},{"issue":"24","key":"651_CR58","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927\u201338.","journal-title":"JAMA"},{"issue":"4","key":"651_CR59","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang Y-C, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972\u201380.","journal-title":"J Clin Endocrinol Metab"},{"key":"651_CR60","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bone.2013.11.002","volume":"59","author":"A Parthan","year":"2014","unstructured":"Parthan A, Kruse M, Agodoa I, Silverman S, Orwoll E. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective. Bone. 2014;59:105\u201313.","journal-title":"Bone"},{"issue":"7","key":"651_CR61","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.clinthera.2017.05.348","volume":"39","author":"CE O\u2019Hanlon","year":"2017","unstructured":"O\u2019Hanlon CE, Parthan A, Kruse M, Cartier S, Stollenwerk B, Jiang Y, et al. A model for assessing the clinical and economic benefits of bone-forming agents for reducing fractures in postmenopausal women at high, near-term risk of osteoporotic fracture. Clin Ther. 2017;39(7):1276\u201390.","journal-title":"Clin Ther"},{"issue":"10","key":"651_CR62","first-page":"1089","volume":"25","author":"QA Le","year":"2019","unstructured":"Le QA. Patient-level modeling approach using discrete-event simulation: a cost-effectiveness study of current treatment guidelines for women with postmenopausal osteoporosis. J Manag Care Spec Pharm. 2019;25(10):1089\u201395.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"651_CR63","doi-asserted-by":"publisher","first-page":"A47","DOI":"10.1016\/j.jval.2014.03.281","volume":"17","author":"Y Ding","year":"2014","unstructured":"Ding Y, Hay J. Cost-effectiveness comparison of denosumab and zoledronic acid in the treatment of postmenopausal osteoporosis. Value Health. 2014;17(3):A47.","journal-title":"Value Health"},{"key":"651_CR64","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.semarthrit.2019.01.006","volume":"49","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster J-Y. Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture. Semin Arthritis Rheum. 2019;49:184\u201396.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"651_CR65","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40273-023-01270-x","volume":"41","author":"M Hiligsmann","year":"2023","unstructured":"Hiligsmann M, Silverman SS, Singer AJ, Pearman L, Mathew J, Wang Y, et al. Cost-effectiveness of sequential abaloparatide\/alendronate in men at high risk of fractures in the United States. Pharmacoeconomics. 2023;41(7):819\u201330.","journal-title":"Pharmacoeconomics"},{"key":"651_CR66","unstructured":"Institute for Clinical and Economic Review. 2020\u20132023 Value Assessment Framework 2020. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_2020_2023_VAF_102220.pdf. Accessed 7 Apr 2026."},{"key":"651_CR67","unstructured":"Sparks G, Kirzinger A, Montero A, Valdes I, Hamel L. Public opinion on prescription drugs and their prices. https:\/\/www.kff.org\/health-costs\/public-opinion-on-prescription-drugs-and-their-prices\/. Accessed 24 Nov 2025."},{"key":"651_CR68","unstructured":"Medicaid. Cost Sharing. https:\/\/www.medicaid.gov\/medicaid\/cost-sharing#:~:text=Medicaid%20rules%20give%20states%20the,more%20information%20in%20Prescription%20Drugs. Accessed 24 Nov 2025"},{"key":"651_CR69","unstructured":"Centers for Medicare & Medicaid Services. 2025 Marketplace Integrity and Affordability Final Rule, 2025. Marketplace Integrity and Affordability Final Rule."},{"key":"651_CR70","unstructured":"Association for Accessible Medicines. The U.S. Generic & Biosimilar Medicines Savings Report 2023, Last update: September 2023."},{"key":"651_CR71","unstructured":"The Financial Stability of America\u2019s Hospitals and Health Systems Is at Risk as the Costs of Caring Continue to Rise. 2023. https:\/\/www.aha.org\/guidesreports\/2024-05-01-2023-costs-caring. Accessed 26 July 2024."},{"issue":"11","key":"651_CR72","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10233","volume":"3","author":"T Mori","year":"2019","unstructured":"Mori T, Crandall CJ, Ganz DA. Cost effectiveness of sequential teriparatide\/alendronate versus alendronate alone strategies in high risk osteoporotic women in the US: analyzing the impact of generic\/biosimilar teriparatide. JBMR Plus. 2019;3(11):e10233.","journal-title":"JBMR Plus"},{"issue":"1-2","key":"651_CR73","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/21678421.2018.1541095","volume":"20","author":"SB Rutkove","year":"2019","unstructured":"Rutkove SB, Qi K, Shelton K, Liss J, Berisha V, Shefner JM. ALS longitudinal studies with frequent data collection at home: study design and baseline data. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(1\u20132):61\u20137.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"1","key":"651_CR74","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00198-003-1490-4","volume":"15","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis J, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, et al. Mortality after osteoporotic fractures. Osteoporos Int. 2004;15(1):38\u201342.","journal-title":"Osteoporos Int"},{"issue":"1","key":"651_CR75","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11657-016-0272-5","volume":"11","author":"BR Lindsay","year":"2016","unstructured":"Lindsay BR, Olufade T, Bauer J, Babrowicz J, Hahn R. Patient-reported barriers to osteoporosis therapy. Arch Osteoporos. 2016;11(1):19.","journal-title":"Arch Osteoporos"},{"issue":"2","key":"651_CR76","first-page":"72","volume":"34","author":"MD Iversen","year":"2011","unstructured":"Iversen MD, Vora RR, Servi A, Solomon DH. Factors affecting adherence to osteoporosis medications: a focus group approach examining viewpoints of patients and providers. J Geriatr Phys Ther. 2011;34(2):72\u201381.","journal-title":"J Geriatr Phys Ther"},{"key":"651_CR77","doi-asserted-by":"crossref","unstructured":"Wells GA, Hsieh S-C, Zheng C, Peterson J, Liu W, Kelly SE, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2022(5).","DOI":"10.1002\/14651858.CD004523.pub4"},{"issue":"4","key":"651_CR78","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s00223-008-9117-6","volume":"82","author":"M Hiligsmann","year":"2008","unstructured":"Hiligsmann M, Ethgen O, Richy F, Reginster JY. Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int. 2008;82(4):288\u201392.","journal-title":"Calcif Tissue Int"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00651-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-026-00651-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00651-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:02:41Z","timestamp":1784289761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-026-00651-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["651"],"URL":"https:\/\/doi.org\/10.1007\/s41669-026-00651-0","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jeanine Flanigan, Mike Tindal, Marion Schauf, and Edward Li are employees of and own stock in Sandoz Inc. Sarah Kane, Fatemeh Mirzayeh Fashami, Anna Zhou, and Lamees Almuallem are employed by EVERSANA, which received a consultancy fee for development of this analysis. Gary Lyman received a consultancy fee for supervising the model and final manuscript.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The model was populated using data from publicly available literature sources. No additional data beyond what is published in the literature is available.","order":5,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Microsoft Excel model was provided to the manuscript reviewers during the peer review process; however, the model and any associated code are proprietary and will not be available in the public domain.","order":6,"name":"Ethics","label":"Material and\/or code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Concept and design (JF, EL, SK, FMF, AZ, MT, MS); acquisition of data (SK, FMF, AZ); modeling and interpretation of data (SK, FMF, AZ, LA); drafting of the manuscript (SK, FMF, AZ, LA); critical revision of the manuscript for important intellectual content (JF, EL, SK, AZ, MT, MS, GL); and supervision (JF, EL, MT, MS, GL). All authors confirm that they have read and approved the final version of the manuscript.","order":7,"name":"Ethics","label":"Author contribution","group":{"name":"EthicsHeading","label":"Declarations"}}]}}